Baymatob has successfully completed a competitive selection process to join this year’s cohort of the ANDHealth+ commercialisation acceleration program, funded by the Australian Government’s Medical Research Future Fund (MRFF). Baymatob is joined by four other Australian Digital Health businesses in this cohort, who were assessed by ANDHealth’s multi-disciplinary and multi-sectoral judging panel and International Investment Committee.
ANDHealth Managing Director and CEO Bronwyn Le Grice said “…the ANDHealth+ program ensures we can support those Australian digital health companies with the greatest chance of commercialising novel digital health technologies in the Australian and international markets.”
This program allows Baymatob to work with not only ANDHealth but experienced investors, clinicians, founders, and executives in the digital health space through a Multi-sectoral Industry Advisory Panel dedicated to the company, and the International Investment Advisory Committee. These experts will consult with Baymatob to develop and execute on two interrelated projects to drive growth in the business, and achieve clinical and commercial milestones.
Baymatob CEO, Tara Croft, said “At Baymatob, we are looking to create an entirely new standard of care for mothers and their babies via our digital platform, Oli. To achieve the breadth of impact that we intend for Oli, getting our commercial strategy and execution right is just as important as the technology and clinical evidence we are generating. That is why we are so thrilled to be a part of this year's ANDHealth+ cohort, as we believe the support and expertise the program offers will be extremely helpful on our path to success.”
For more information see: https://www.andhealth.com.au/news/22-5m-digital-health-accelerator-announces-second-cohort